Our Investment Manager actively manages a strategic portfolio of 14 companies, which are diversified across different stages of the development cycle and a range of therapeutic areas.
Our business in numbers
Unless stated all financials at 31 March 2025
Portfolio companies
Value of life science portfolio
Capital pool
Members of the SIML team
SIML investment team with PhDs
Portfolio company Board seats
To maximise value and transform patient outcomes
We have a portfolio of leading life science companies that are seeking to deliver transformational treatments to patients.
A multidisciplinary team
Our Investment Manager's team members have deep technical scientific backgrounds, supplemented by strong commercial experience ranging from venture capital investment to pharmaceutical launch.
Supporting UK life science
The UK has a thriving life sciences industry and world-class research infrastructure. Syncona is committed to supporting this via its work with academics, its portfolio companies, and co-investors, as well as through its membership of the BioIndustry Association (BIA), the voice of the life sciences and biotech industry in the UK.
